CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020

被引:381
作者
Schillie, Sarah [1 ]
Wester, Carolyn [1 ]
Osborne, Melissa [1 ]
Wesolowski, Laura [1 ]
Ryerson, A. Blythe [1 ]
机构
[1] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA
来源
MMWR RECOMMENDATIONS AND REPORTS | 2020年 / 69卷 / 02期
关键词
VIRUS-INFECTION; COST-EFFECTIVENESS; NATURAL-HISTORY; VERTICAL TRANSMISSION; DRUG DIVERSION; PREGNANT-WOMEN; CARE; UNIVERSAL; PREVALENCE; ATTITUDES;
D O I
10.15585/mmwr.rr6902a1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis C virus (HCV) infection is a major source of morbidity and mortality in the United States. HCV is transmitted primarily through parenteml exposures to infectious blood or body fluids that contain blood most commonly through injection drug use. No vaccine against hepatitis C exists and no effective pre- or postexposure prophylaxis is available. More than half of persons who become infected with HCV will develop chronic infection. Direct-acting antiviral treatment can result in a virologic cure in most persons with 8-12 weeks of all-oral medication regimens. This report augments (i.e., updates and summarizes) previously published recommendations from CDC regarding testing for HCV infection in the United States (Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rec 2012;61 [No. RR-4]). CDC is augmenting previous guidance with two new recommendations: 1) hepatitis C screening at least once in a lifetime for all adults aged >= 18 years, except in settings where the prevalence of HCV infection is <0.1% and 2) hepatitis C screening for all pregnant women during each pregnancy, except in settings where the prevalence of HCV infection is <0.1%. The recommendation for HCV testing that remains unchanged is regardless of age or setting prevalence, all persons with risk factors should be tested for hepatitis C, with periodic testing while risk factors persist. Any person who requests hepatitis C testing should receive it, regardless of disclosure of risk, because many persons might be reluctant to disclose stigmatizing risks.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 103 条
[1]  
[Anonymous], 2013, Ann Intern Med, V159, pI, DOI 10.7326/0003-4819-159-5-201309030-00677
[2]  
[Anonymous], 1991, MMWR Recomm Rep, V40, P1
[3]  
[Anonymous], AM HLTH RANK UN WOM
[4]  
[Anonymous], VIR HEP SURV US 2017
[5]  
[Anonymous], HLTH INEQUALITY APPL
[6]  
[Anonymous], 2019, WELLCOME OPEN RES
[7]  
[Anonymous], ANN INTERN MED
[8]  
[Anonymous], HIGHL PRESCR INF
[9]  
[Anonymous], 2019, HCV GUID REC TEST MA
[10]  
[Anonymous], 2018, PRINCIPLES PRACTICE